ERBB2 and neoplasm: The development of fluorescent probes targeting tumor-specific biomarkers—such as carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), human epidermal growth factor receptor 2 (HER2), or other gastric cancer-associated antigens—holds the potential to truly revolutionize surgical oncology (25).